Skip to content
akaturk Academic measurement
Sign in Sign up

OpenAlex topic

Vitamin K Research Studies

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 1,431 works 7 author topics

Works

1,431 works

  1. Edoxaban versus Warfarin in Patients with Atrial Fibrillation 2013
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens…

  2. Edoxaban versus Warfarin in Patients with Atrial Fibrillation 2013
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens…

  3. Edoxaban versus Warfarin in Patients with Atrial Fibrillation 2013
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens…

  4. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation ROCKET AF 2014
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.7%

    BACKGROUND: Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Anta…

  5. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack a subgroup analysis of ROCKET AF 2012
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.7%

    No abstract yet.

  6. Association of subclinical vitamin D deficiency in newborns with acute lower respiratory infection and their mothers 2009
    YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 98.2%

    No abstract yet.

  7. Mutations in the Gene Encoding the RER Protein FKBP65 Cause Autosomal Recessive Osteogenesis Imperfecta 2010
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.7%

    No abstract yet.

  8. Mutations in the Gene Encoding the RER Protein FKBP65 Cause Autosomal Recessive Osteogenesis Imperfecta 2010
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  9. Mutations in the Gene Encoding the RER Protein FKBP65 Cause Autosomal Recessive Osteogenesis Imperfecta 2010
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  10. Mutations in the Gene Encoding the RER Protein FKBP65 Cause Autosomal Recessive Osteogenesis Imperfecta 2010
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  11. Mutations in the Gene Encoding the RER Protein FKBP65 Cause Autosomal-Recessive Osteogenesis Imperfecta 2010
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  12. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF 2016
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.7%

    The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolle…

Academicians

7 academicians